NBE-Therapeutics
Basel
About NBE-Therapeutics
NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $65.7M
- Funding stage: M&A
- Last round: Series C (Jan 2020)
- Website: nbe-therapeutics.com
- Phone: +41616332230
Industries & Categories
Biotechnology, Health Care, Medical, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/nbe-therapeutics-58132 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.